Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2025-03-26 Declaration of Voting R…
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend decisions, and board appointments. This aligns perfectly with the definition of a Declaration of Voting Results (DVA), which reports the official outcomes of shareholder votes at a general meeting.
2025-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding the issuance of new equity-linked instruments (stock options) falls under the category of share-related capital changes.
2025-03-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific director (Byung Girl Rhee) of the company Qurient. This type of filing is a standard regulatory requirement for insider trading/shareholding reporting, which corresponds to the 'Director's Dealing' category.
2025-03-20 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Curient' (주식회사 큐리언트) for the fiscal year ending December 31, 2024. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. This is a comprehensive financial audit document, not an earnings release or a simple announcement, fitting the 'Audit Report' category. FY 2024
2025-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from the company Qurient. It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the current and previous fiscal years. While it contains financial data, it is a standard regulatory disclosure announcement in the Korean market (DART system) notifying the public that the audit report has been submitted. According to the 'Menu vs Meal' rule, this is an announcement of the report rather than the full audit report document itself, and it fits the criteria for a regulatory filing. FY 2024
2025-03-17 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the issuance of new shares, the purpose of the capital raise (operating funds and R&D), the third-party allocation details, and the pricing methodology. This falls under the category of capital structure changes and financing activities.
2025-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.